Geode Capital Management’s GT Biopharma GTBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$131K Sell
10,672
-1,106
-9% -$11.2K ﹤0.01% 4040
2026
Q1
$120K Buy
11,778
+11,008
+1,430% +$150K ﹤0.01% 4086
2025
Q4
$15.1K Sell
770
-189
-20% -$3.36K ﹤0.01% 4409
2025
Q3
$14.2K Buy
959
+6
+0.6% +$224 ﹤0.01% 4438
2025
Q2
$85.4K Buy
953
+30
+3% +$1.94K ﹤0.01% 4104
2025
Q1
$51.7K Buy
923
+327
+55% +$19.2K ﹤0.01% 4193
2024
Q4
$45.5K Sell
596
-6
-1% -$406 ﹤0.01% 4257
2024
Q3
$34.5K Buy
602
+155
+35% +$9.25K ﹤0.01% 4332
2024
Q2
$31.7K Hold
447
– – ﹤0.01% 4377
2024
Q1
$49.8K Sell
447
-3
-0.7% -$396 ﹤0.01% 4322
2023
Q4
$86K Hold
450
– – ﹤0.01% 4227
2023
Q3
$81.4K Buy
450
+152
+51% +$31.4K ﹤0.01% 4311
2023
Q2
$69.7K Hold
298
– – ﹤0.01% 4439
2023
Q1
$123K Hold
298
– – ﹤0.01% 4261
2022
Q4
$199K Sell
298
-1
-0.3% -$1.25K ﹤0.01% 4107
2022
Q3
$394K Sell
299
-57
-16% -$109K ﹤0.01% 3852
2022
Q2
$799K Sell
356
-127
-26% -$241K ﹤0.01% 3523
2022
Q1
$1.04M Sell
483
-34
-7% -$75K ﹤0.01% 3599
2021
Q4
$1.18M Sell
517
-49
-9% -$183K ﹤0.01% 3633
2021
Q3
$2.86M Buy
566
+104
+23% +$782K ﹤0.01% 3205
2021
Q2
$5.37M Buy
462
+288
+166% +$2.99M ﹤0.01% 2853
2021
Q1
$891K Buy
+174
New +$760K ﹤0.01% 3604

Other funds holding GTBP

Geode Capital Management's GTBP Position: Q2 2026 in Review

Geode Capital Management reduced its GT Biopharma (GTBP) stake by 9.4% in Q2 2026, selling an estimated $11.2K and leaving 10,672 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Geode Capital Management first reported a position in GTBP in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.37M in Q2 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Geode Capital Management held 10,672 shares of GT Biopharma worth $131K as of Q2 2026.
  • Geode Capital Management sold 1,106 GT Biopharma shares in Q2 2026, an estimated $11.2K.
  • GT Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4040 holding.
  • Geode Capital Management first reported a position in GT Biopharma in Q1 2021 and has held it in 22 quarters since.
  • Geode Capital Management's GT Biopharma position peaked at $5.37M in Q2 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.